TrialDiabetes, obesity & metabolism2021

Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials.

Carine Beysen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.